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Abstract Current treatment of organophosphate poisoning
is insufﬁcient, and survivors may suffer from long-lasting
adverse effects, such as cognitive deﬁcits and sleep-wake
disturbances. In the present study, we aimed at developing
a guinea pig model to investigate the beneﬁts of immediate
and delayed stand-alone therapy on the development of
clinical signs, EEG, heart rate, respiration and AChE
activity in blood and brain after soman poisoning. The
model allowed the determination of the therapeutic effects
at the short-term of obidoxime, atropine and physostig-
mine. Obidoxime exerted the highest therapeutic efﬁcacy
at administration of the lowest dose (3.1 mg/kg i.m.),
whereas two higher doses (9 and 18 mg/kg) were less
effective on most parameters. Addition of atropine at 0.03
and 3 mg/kg (i.m.) to the treatment did not improve the
therapeutic effects of obidoxime alone. Physostigmine
(0.8 mg/kg im) at 1 min after poisoning increased mor-
tality. Two lower doses (0.1 and 0.3 mg/kg i.m.) showed
improvements on all parameters but respiration. The mid-
dle dose was most effective in preventing seizure devel-
opment and therefore assessed as the most efﬁcacious dose.
Combined treatment of obidoxime and physostigmine
shortened the duration of seizures, if present, from up to
80 min to *10–15 min. In practice, treatment will be
employed when toxic signs appear, with the presence of
high levels of AChE inhibition in both blood and brain.
Administration of physostigmine at that moment showed to
be redundant or even harmful. Therefore, treatment of OP
poisoning with a carbamate, such as physostigmine, should
be carefully re-evaluated.
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Introduction
Organophosphates (OPs) are highly toxic chemicals, which
mainly exert their toxicity by irreversible inhibition of
acetylcholinesterase (AChE) and the consequent excessive
and deleterious buildup of acetylcholine (Maxwell et al.
2006). Nerve agents are the most toxic OPs and might be
used in military conﬂicts or in terrorist attacks, such as
those in the Tokyo subway station in 1995 (Suzuki et al.
1995). The buildup of acetylcholine (ACh) following OP
exposure in central and peripheral synapses leads to typical
cholinergic signs due to overstimulation of nicotinergic and
muscarinergic synapses. This overstimulation evolves into
hypersecretions, failure of neuromuscular transmission,
seizures, convulsions and eventually death due to respira-
tory failure (Shih and McDonough 1997; van Helden and
Bueters 1999). In preclinical studies, the currently avail-
able treatment regimens appeared to be ineffective in
preventing this, giving way to seizures that might induce
brain damage and concomitant deﬁcits in cognition and
attention even when they are short-lasting (Joosen et al.
2009; Raveh et al. 2003).
Treatment is generally aimed at three targets. The ﬁrst
one, achieved by oxime treatment, is breaking the covalent
bond of the OP from the serine residue in the active site of
AChE. However, no broad-spectrum oximes are available
to manage the chemistry of all nerve agents (Aas 2003;
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DOI 10.1007/s00204-010-0571-3Maxwell et al. 2008). Moreover, none of the oximes are
capable to reactivate inhibited and ‘‘aged’’ AChE, i.e. when
the alkyl tail of the OP molecule has gone, thereby ren-
dering the remaining bond virtually irreversible (Berman
and Decker 1986). The second target of treatment is
directed towards blocking muscarinic overstimulation
using compounds such as atropine sulphate. Although
rather effective at very high doses, atropine rapidly looses
efﬁcacy when administered at low doses or after develop-
ment of full-blown seizures (Shih and McDonough 2000).
The ﬁnal treatment is aimed at terminating seizures by
benzodiazepines in order to prevent brain injury. Recent
research suggested that seizures lasting no longer than
10 min did not induce visible brain damage but rather
inhibited neurogenesis resulting in impaired cognitive
performance (Joosen et al. 2009). These and other ﬁndings
show the need to advance understanding of the toxic as
well as the antidotal mechanisms in order to obtain more
effective medical countermeasures.
Therefore, the present study was aimed at investigating
several features of OP poisoning and treatment. The nerve
agent soman was chosen as a model compound because it
is expected to have the highest risk of inducing brain
damage (McDonough et al. 1999, 2000), and after binding
to AChE, it ages very rapidly. This makes poisoning with
soman less prone to successful treatment with any of the
existing oximes, such as 2-PAM, obidoxime and HI-6. It is
known that preserving or restoring AChE pools is one of
the most efﬁcacious treatments in case of nerve agent
poisoning and most effective when employed very rapidly
after poisoning. Although the reactivating capacity of
obidoxime towards soman-inhibited AChE activity is
known to be very low, this oxime was used in the present
experiments for two reasons. The ﬁrst reason was purely
practical in that obidoxime is currently in use as an auto-
injector compound. Second, the use of obidoxime would
enable the identiﬁcation of other targets for obidoxime
efﬁcacy than AChE reactivation alone (Maxwell et al.
2006).
Recently, post-poisoning treatment with carbamates has
been proposed. For example, physostigmine, previously
shown to be highly effective as pretreatment against OP
poisoning, was effective against 5 LD50 soman in guinea
pigs, administered 1 min post-poisoning in combination
with scopolamine and HI-6 (Wetherell et al. 2006, 2007).
Also galantamine showed efﬁcacy when administered
shortly after poisoning with VX or soman (Albuquerque
et al. 2006; Hilmas et al. 2009).
In the present study, a soman-poisoned guinea pig model
was developed to enable the investigation of the impact of
different doses of soman and subsequent relief of toxic
signs by different treatment protocols. The guinea pig is the
most widely accepted non-primate model for predicting
treatment efﬁcacy for nerve agent poisoning in primate
species (Dirnhuber et al. 1979; Gordon et al. 1978). Our
approach enabled online monitoring of vital physiological
signs and off-line determination of biochemistry in terms
of AChE and butyrylcholinesterase (BuChE) activity. Both
physiology and biochemistry were investigated for being
suitable parameters predictive for clinical outcome. The
therapeutic efﬁcacy of several treatment combinations of
obidoxime, atropine sulphate and physostigmine, admin-
istered at 1 or 10 min following poisoning, was tested. The
research was focused on the identiﬁcation of the contrib-
uting role of physostigmine in the treatment.
Methods
Animals
Male Dunkin Hartley guinea pigs (Crl:HA) obtained from
Charles River (Maastricht, The Netherlands) were used in
the present study. Prior to the experiments, they were
housed with two animals per cage and allowed to get
accustomed to standard conditions for 1 week. Room
temperature was kept at 19–22C, and relative humidity
was maintained at 55–65%, and lights were on from 7 am
to 7 pm. Acidiﬁed water and standard guinea pig chow
(Teklad global diet 2040, Harlan, Horst, The Netherlands)
were available ad libitum. The experiments described
received prior approval from the TNO Animal Ethical
Committee.
Chemicals
Hypnorm
 (fentanyl/ﬂuanisone) was purchased from
Janssen Pharmaceutica (Beerse, Belgium), and Dormi-
cum
 (midazolam) was delivered by Roche Nederland BV
(Mijdrecht, The Netherlands). Soman (O-Pinacolyl
methylphosphonoﬂuoridate) was obtained from the stocks
of TNO Defence, Security and Safety and of purity C98%
(GC). The other chemicals used were of standard purity
and purchased from renowned companies.
Study design
The design of the study is presented in Fig. 1. After
obtaining baseline values of the indicated parameters for
30 min, the guinea pigs were poisoned with soman (30; 37
or 44 lg/kg s.c.; corresponding to *1.2; 1.5 and 1.8 24 h
LD50, respectively, (Gordon and Leadbeater 1977), fol-
lowed by i.m. treatment 1 or 10 min later. The experiment
was divided in four parts: establishment of a model dose
for soman; efﬁcacy of conventional treatment by obidox-
ime and atropine; efﬁcacy of physostigmine; and the
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123efﬁcacy of postponed treatment (Table 1). A control group
was injected with saline (s.c.) followed by an i.m. saline
injection. At the indicated time points (r), blood samples
were drawn from the ear vein to assess AChE activity.
Following poisoning, the guinea pigs were observed for
toxic cholinergic signs such as chewing, tremor, salivation
and convulsions. Clear chewing movements involving the
entire head were scored as chewing, often accompanied by
extensive drooling (salivation) later on. Involuntary shak-
ing of parts of the body or head was scored as tremor.
Convulsions were deﬁned as involuntary movements of the
entire body, while the animal looks dissociated from its
environment. At the end of the experiment, 90 min after
poisoning, different brain parts (hippocampus, striatum and
medulla oblongata) were isolated for AChE level
determination.
Surgical procedures
Guinea pigs were anaesthetized with 6 ml/kg FFM-mix
(1.25 mg/ml midazolam, 2.5 mg/ml ﬂuanisone, 0.079 mg/ml
fentanyl citrate) via a single i.p. injection. Premedication
with 0.05 mg/kg atropine sulphate (s.c.) was administered
to prevent respiratory arrest. Two stainless steel screws
(A8.0 and P1.2 mm relative to bregma and 1 mm from the
sagittal suture) placed at the dura mater, ﬁxed to a plug,
served as EEG electrodes. To obtain an ECG signal, two
leads sutured in the superﬁcial muscles under the skin just
Fig. 1 Overview of the experimental design. Before and after
poisoning, EEG, ECG, respiration and clinical signs were continu-
ously monitored. Every 10 min after poisoning, blood was drawn
from the ear vein to determine blood ChE activity
Table 1 Overview of experimental groups
Experiment Exposure Treatment Signs
Soman
(lg/kg s.c.)
Obidoxime
(mg/kg i.m.)
Physostigmine
(mg/kg i.m.)
Atropine sulphate
(mg/kg i.m.)
Time of treatment
(min after soman)
Seizures Convulsions 90-min survival
(n)% ( n)% ( n)%
Model 0 – – – – 0/4 0 0/4 0 4/4 100
30 – – – 1 6/6 100 6/6 100 5/6 83
37 – – – 1 6/6 100 6/6 100 3/6 50
44 – – – 1 6/6 100 6/6 100 1/6 17
Conventional 30 3.1 – – 1 4/6 67 2/6 33 6/6 100
30 9 – – 1 5/6 83 4/6 67 6/6 100
30 18 – – 1 5/6 83 4/6 67 6/6 100
30 – – 3 1 5/6 83 2/6 33 6/6 100
30 3.1 – 0.03 1 5/5 100 4/5 80 5/5 100
30 3.1 – 3 1 4/5 80 1/5 20 4/5 80
44 3.1 – 3 1 6/6 100 6/6 100 5/6 83
Physostigmine 30 – 0.1 – 1 4/4 100 1/4 25 4/4 100
30 – 0.3 – 1 2/6 33 2/6 33 6/6 100
30 – 0.8 – 1 1/2 50 2/2 100 0/2 0
30 3.1 0.1 – 1 3/5 60 1/5 20 5/5 100
30 3.1 0.3 – 1 2/6 33 1/6 17 6/6 100
30 3.1 0.8 – 1 4/4 100 4/4 100 2/4 50
30 3.1 0.3 3 1 1/6 17 0/6 0 6/6 100
Postponed 30 3.1 0.3 – 10 4/6 67 3/6 50 2/6 33
30 3.1 0.3 3 10 6/6 100 6/6 100 5/6 83
30 3.1 – 3 10 6/7 86 5/7 71 7/7 100
The left column refers to the corresponding results section. Time and dose of treatments applied, occurrence of seizures and convulsions, and
survival rate are shown from left to right
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123below the right collarbone and between the second and
third rib (Lead II conﬁguration) and also ﬁxed to the plug.
The plug and the electrodes were ﬁxed to the skull with
dental cement.
Acquisition and analysis of EEG and respiration
Before and after poisoning, the animals were placed in a
whole-body plethysmograph (Buxco sytems XA, USA)
cage to monitor their respiration characteristics. Among
other parameters, P-enhanced (Penh), an arbitrary value for
bronchoconstriction, and respiratory minute volume were
calculated from the signal using IOX software (EMKA
technologies, France).
EEG signals were obtained using the PhysioTel telem-
etry system from Data Sciences Inc. (DSI) using the ML2-
11-EET-F40 transmitter. The transmitter was attached to
the plug ﬁxed on the guinea pig’s skull. A receiver board
measured the signal from the transmitter, which was con-
solidated and stored on an IBM-compatible personal
computer via a Data Exchange matrix at 100-Hz sampling
frequency. By visual inspection of the EEG, the starting
and ending of seizures, deﬁned as amplitudes increasing
three times over baseline, were scored. Additionally, FFT
analysis using 10-s epochs was performed to calculate the
total power in the spectrum, thereby serving as a semi-
quantitative measure of seizure activity. Animals were
awake during the measurement.
Enzyme activity
The brain parts were homogenized (900 rpm, 10% w/v
homogenate) in ice-cold TENT buffer, which consisted of
50 mM Tris, 5 mM EDTA, 1 M NaCl and 1% v/v Triton
X-100, pH 7.4. The homogenates were centrifuged at
12,000g in an Eppendorf centrifuge at 4C, and superna-
tants were immediately frozen in liquid nitrogen and stored
at -20C until analysis of enzyme activity. Blood samples
drawn from the ear vein were diluted 10 times in 1%
saponin in MQ, frozen in liquid nitrogen and stored at
-20C until analysis.
Tissue supernatants were analysed for AChE activity
using the method described by Ellman et al. (1961),
modiﬁed for analysis in a 96-well plate reader. Shortly,
samples were diluted in 0.8 mM DTNB (5,50-dithio-bis-
(2-nitrobenzoic acid)). To 100 ll of diluted sample, 100 ll
of 0.8 mM b-methylacetylthiocholine iodide was added, in
quadruple. For blood samples, 0.8 mM of butyrylthio-
choline (BuSChI) was added to separate portions of 100 ll.
The delta OD per min at 415 nm at ambient temperature
served as measurement for ChE activity.
Guinea pig AChE does not react with BuSChI, rendering
theBuChEactivitydeterminedanappropriaterepresentation
of BuChE activity. Brain samples showed no reactivity
towards BuSChI. However, AChE activity in blood had to
be corrected for cross-reactivity of b-methylacetylthio-
choline with BuChE. The maximum velocity turnover of
b-methylacetylthiocholine by BuChE was 47% of that of
BuSChI, calculated from separate experiments in which
isolated guinea pig AChE and plasma BuChE were incu-
bated with both substrates. Therefore, 47% of the extinc-
tion measured with BuSChI as substrate was subtracted
from the extinction measured with b-methylacetylthio-
choline, which reacts at a similar rate with AChE and
BuChE. A similar adaptation has been described by Bosgra
et al. (2009). Enzyme activity in the tissue supernatants
was normalized versus the average enzyme activity of six
control animals. AChE and BuChE activities in blood were
normalized versus the baseline sample.
Data presentation and statistical analysis
All data were analysed using one-way ANOVA or
MANOVA followed by Dunnett’s or Tukey’s post hoc test
using soman or saline as control animals using SPSS
statistical software. Results were considered signiﬁcant for
P\0.05.
For determination of continuous relationships between
blood AChE activity and occurrence of clinical signs,
logisticregressionanalysiswasperformed.AChEactivityof
similarly treated animals was coupled to presence of a sign
(1) or absence of sign (0). To analyse the effects of soman,
animals injected with soman only were included in the
analysis (n = 18). To analyse the effect of separate treat-
ments, animals were grouped into soman-poisoned animals
treatedwithobidoximealone,physostigminealone,atropine
alone or the combinations thereof administered at 1 min
after poisoning. Using logistic regression analysis, proba-
bility for each level of AChE activity was calculated.
Results
Soman-poisoned guinea pig model
In the ﬁrst set of experiments, various soman doses (30, 37
and 44 lg/kg) were tested for their induction of clinical
signs and effects on physiology and biochemistry. A dose-
dependent effect on survival was found during the 90-min
experimental period (See Fig. 2; Table 1). Apart from
survival rate, no differences regarding the appearance of
other clinical signs were found between the different
soman doses, albeit that the onset times of clinical signs, if
present, were signiﬁcantly shorter after poisoning with
44 lg/kg of soman (s.c.) compared to the lower doses
(Fig. 2).
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123Cholinesterase activity in different brain regions
(AChE) at 90 min and in blood (AChE and BuChE) at
10 min after poisoning was dose dependently inhibited by
soman (MANOVA, P\0.001). However, there were no
signiﬁcant differences in inhibition between the different
doses [Tukey HSD post hoc test P[0.05 (Table 2)].
Regardless the dose, all animals poisoned with soman
developed seizures within 5–30 min, albeit that animals
poisoned with the highest dose tended to develop full-
blown seizures more rapidly (Fig. 3a). Seizure develop-
ment is characterized by an increase in total power of the
fast Fourier transformation of the spectrum of the EEG
signal (FFT) compared to seizure-free EEG. In contrast to
animals poisoned with 30 or 37 lg/kg, which merely sur-
vived the 90-min observation period, animals poisoned
with 44 lg/kg died rapidly after onset of seizures. In sur-
viving animals, seizures continued with similar intensity
over the entire 90-min observation period (Fig. 3a).
Additionally, heart rate and respiratory parameters were
measured as main vital parameters. There were no obvious
and consistent effects of soman on heart rate (not shown),
whereas effects on respiration parameters were clearly
present. After soman poisoning, a clear and signiﬁcant
increase in respiratory minute volume (RMV) compared to
control animals was present (Fig. 3b). Soman poisoning
also resulted in an increase in bronchoconstriction, which
was, however, not signiﬁcant (not shown). For these
physiological parameters, no dose–response effect of
soman was observed.
Efﬁcacy of conventional therapy
In animals poisoned with 30 lg/kg s.c. soman, compo-
nents of the treatment currently in use were tested. The
effects of different doses and combinations of obidoxime
(3.1, 9 and 18 mg/kg) and atropine (0.03 and 3 mg/kg)
were tested. None of the obidoxime doses tested induced
a signiﬁcant reactivation of AChE or BuChE in blood at
any time point (not shown). Only a dose of 3.1 mg/kg
obidoxime had induced a signiﬁcant increase in AChE
activity in the medulla oblongata at 90 min after
poisoning (Fig. 4a).
Analysis of the occurrence of clinical signs (Table 1)
showed that only the lowest dose of obidoxime (3.1 mg/kg)
prevented the development of convulsions in 67% of ani-
mals. Although convulsions were prevented in a high
number of animals, seizures were prevented in a
low number of animals (33%). Addition of either 0.03 or
3 mg/kg atropine to the treatment did not further improve
this. None of these treatments had a signiﬁcant effect on
the onset time of clinical signs, although the increase in
EEG power over time (Fig. 5a) showed some delay in
seizure onset. Only the highest dose of atropine (3 mg/kg),
either with or without obidoxime, prevented the develop-
ment of salivation, in contrast to the autoinjector-equiva-
lent dose of 0.03 mg/kg.
Regarding the respiration parameters, the lowest dose
of obidoxime (3.1 mg/kg) showed a slight and statisti-
cally insigniﬁcant improvement of respiratory minute
volume (Fig. 6a). Addition of atropine to the treatment
with obidoxime showed some positive but insigniﬁcant
effect on RMV (Fig. 6a), whereas atropine alone did not
show any improvement at all. In contrast to no treat-
ment, treatment with the highest dose of obidoxime
induced a clear effect on heart rate. A pressor effect
directly after injection of obidoxime (i.m.) was followed
by a depressant effect at *45 min after injection (not
shown).
Fig. 2 Average onset times of clinical signs after different doses of
soman. Results are presented as means ± SEM. Onset times of
clinical signs in animals poisoned with 44 lg/kg soman were
signiﬁcantly shorter than in animals poisoned with 30 or 37 lg/kg
(one-way ANOVA, within factor signs and between factor dose,
P\0.05 followed by Tukey’s post hoc test,*, P\0.001)
Table 2 Relative residual ChE activity in blood at 10 min and in
different brain areas at 90 min post-poisoning
% ChE activity in
blood and brain parts
Soman dose (lg/kg s.c.)
30 37 44
Blood
AChE 0.9 ± 1.2 3.9 ± 2.8 11.0 ± 16.1
BuChe 3.5 ± 0.6 8.4 ± 1.5 28.6 ± 7.4
Brain
Medulla oblongata 23.9 ± 3.3 19.7 ± 6.0 11.2 ± 5.2
Striatum 13.1 ± 2.6 12.8 ± 5.7 9.1 ± 1.5
Hippocampus 10.0 ± 3.4 4.7 ± 2.4 2.0 ± 1.1
High levels of inhibition of AChE and BuChE are achieved in blood
and in brain. Enzyme activity was signiﬁcantly lower than that of
unpoisoned control animals (100% activity), and no difference
between soman doses was found (MANOVA followed by Tukey HSD
post hoc test)
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123To investigate the extent of efﬁcacy against a higher dose
of soman, the optimal obidoxime treatment (3.1 mg/kg)
combined with atropine sulphate was tested against
44 lg/kg of soman s.c. Although this treatment promoted
survival, none of the other physiological effects, such as
convulsions or seizure development and respiratory effects,
were prevented (data not shown).
Efﬁcacy of physostigmine
The therapeutic efﬁcacy of physostigmine as immediate
treatment in case of organophosphate poisoning was tested
in three different doses: 0.1; 0.3 and 0.8 mg/kg i.m.,
administered at 1 min after soman poisoning. In particular,
the middle dose (0.3 mg/kg) showed a major improvement
on most parameters. Only a small proportion of the animals
treated with this dose of physostigmine showed the
development of seizures and convulsions (2/6 and 1/6,
respectively, see Table 1). Additionally, soman-induced
effects on respiration were prevented in animals treated
with 0.3 mg/kg of physostigmine, but not by the other
doses (Fig. 6b). This was accompanied by high residual
AChE activity in blood and brain regions (Fig. 4b).
Treatment with the highest dose of physostigmine, 0.8 mg/kg,
accelerated the development of clinical signs. In addition
to an increase in RMV, these animals showed high levels
of bronchoconstriction. In contrast to untreated animals,
these animals died within 30–45 min after poisoning, in
spite of residual AChE activity similar to that of animals
treated with 0.3 mg/kg. The lowest dose of physostigmine,
0.1 mg/kg, prevented the development of convulsions in
Fig. 3 a Effects of different
doses of soman on total power
in EEG. b respiratory minute
volume (RMV). Results are
presented as mean ± SEM. No
signiﬁcant differences were
observed between the different
soman doses
Fig. 4 a AChE activity in hippocampus, striatum and medulla
oblongata (HIPP, STR and MO) 90 min after poisoning with soman
and subsequent treatment. The effect of obidoxime (3.1, 9 and
18 mg/kg) and atropine (3 mg/kg) 1 min after poisoning with
30 lg/kg soman. b Efﬁcacy of addition of physostigmine (0.1 and
0.8 mg/kg). c the effects of treatments postponed to 10 min. Results
are presented as mean ± SEM and analysed by MANOVA followed
by Tukey’s HSD post hoc test. *indicates signiﬁcant (P\0.05)
compared to soman alone
b
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123ﬁve out of six animals, but not seizures. Residual AChE
activity in the brains of these animals showed to be lower
than in the animals treated with other physostigmine doses
(Fig. 4b). In particular, AChE activity showed to be pre-
served by physostigmine, and no residual BuChE activity
was detected in blood.
When different physostigmine doses were combined
with the most efﬁcacious dose of obidoxime (3.1 mg/kg),
again the dose of 0.3 mg/kg physostigmine showed the
highest efﬁcacy. Seizure development was prevented in
most animals, and if present, they only lasted for a
maximum of 15 min (Fig. 5b). The highest dose of phy-
sostigmine (0.8 mg/kg) combined with obidoxime also
aggravated signs, including survival (3/6 animals died
within 90 min), but the effects were less deleterious
compared to physostigmine (0.8 mg/kg) treatment alone.
Physostigmine 0.1 mg/kg combined with obidoxime
showed some efﬁcacy on residual enzyme activity and
accordingly on convulsions, seizures and respiration. In
contrast to physostigmine alone, seizures were prevented
in two out of six animals. Residual enzyme activity was
not different between animals treated with physostigmine
alone and physostigmine combined with obidoxime
(Fig. 4b).
The addition of atropine (3 mg/kg) to the most efﬁca-
cious physostigmine/obidoxime combination showed no
improvements compared to the combination without atro-
pine (Fig. 5b). One animal developed seizures for a short
period of *30 min, which was similar to the result shown
in the group of animals treated with physostigmine and
obidoxime. In all animals, RMV increase and broncho-
constriction were prevented, but to a similar extent as in
animals treated with the combination of physostigmine and
obidoxime (Fig. 6b).
Efﬁcacy of postponed treatment
As in practice, treatment will be postponed until overt
signs are present; we also administered the most efﬁca-
cious combination of obidoxime (3.1 mg/kg) and atropine
(3 mg/kg) at 10 min after poisoning with 30 lg/kg soman,
when toxic signs were already visible. These experiments
showed that in that case, the therapeutic efﬁcacy of the
combination nearly completely lost its effectiveness on all
Fig. 5 a Treatment effect on total power in EEG before and after
soman poisoning. Results are presented as 10-min averages ± SEM.
The effect of obidoxime (3.1 mg/kg) and atropine (3 mg/kg) admin-
istered at 1 min after soman poisoning. b The effect of physostigmine
(0.3 mg/kg) alone or as an addition to obidoxime and/or atropine.
c The effect of similar treatments administered at 10 min after
poisoning
b
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123parameters. Salivation was prevented in all animals, but
RMV increase (Fig. 6c) and seizure development were not
affected (Fig. 5c). In two out of six animals, convulsions
were prevented (Table 1), whereas the onset time of
convulsions in the remaining animals tended to be later
(P[0.05).
The combination physostigmine (0.3 mg/kg) and obi-
doxime (3.1 mg/kg), showing outstanding efﬁcacy when
administered at 1 min after poisoning, showed full efﬁcacy
in two out of six animals, but in four out of six animals,
lethality was accelerated when the combination was
administered at 10 min.
The full combination of obidoxime, atropine and phy-
sostigmine also completely lost efﬁcacy, in that seizure
development (Fig. 5c) and increase in RMV (Fig. 6c) were
similar to that of untreated animals. Accordingly, no
improvements in residual AChE activity were found in the
different brain regions, except the physostigmine–obidox-
ime combination, which showed some improvement in the
striatum (Fig. 4c).
Discussion
In the present experiments, a guinea pig model was
developed to study soman poisoning and therapeutic efﬁ-
cacy of immediate and postponed treatment. The guinea
pig soman model doses showed to be suitable for investi-
gating different levels of therapeutic efﬁcacy. First of all,
the lowest dose, 30 lg/kg, showed to be most suitable to
investigate therapeutic effects on physiology, whereas the
highest dose allowed the assessment of efﬁcacy regarding
survival. Seizure development, accompanied by increased
RMV and to a lesser extent to an increase of broncho-
constriction, was present in all animals at all soman doses.
The increase in RMV was primarily mediated by an
increase in tidal volume, rather than by increased respira-
tory frequency. Although this ﬁnding was unexpected, a
pronounced involvement of, in particular, the M1 and M3
mAChRs in the control of respiration might explain the
increased tidal volume and RMV observed after soman
exposure (Boudinot et al. 2008). In addition, bronchorrhea
and bronchoconstriction mediate lower pO2 levels in blood,
thereby stimulating chemoreceptors in the respiratory
centres (Wiener and Hoffman 2004). Bradycardia expected
Fig. 6 a Treatment effect on respiratory minute volume (RMV)
before and after soman poisoning. Results are presented as 10-min
averages ± SEM. The effect of obidoxime (3.1 mg/kg) and atropine
(3 mg/kg) administered at 1 min after soman poisoning. b The effect
of physostigmine (0.3 mg/kg) alone or as an addition to obidoxime
and/or atropine. c The effect of similar treatments administered at
10 min after poisoning
b
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123to be present due to cholinergic overstimulation was
absent, probably due to a sympathetic response. In con-
trast with AChE activity in blood at 10 min post-poisoning,
a soman dose–response effect on AChE activity was
found in all brain regions analysed, resulting in 80–90%
inhibition at 90 min post-poisoning. Similar results were
reported by Shih et al. (2005), who investigated the
differential inhibition of various nerve agent types in sev-
eral organs.
AChE activity in blood mainly serves as biomarker for
exposure and not for toxicity (Lotti 1995). It was shown
previously that AChE activity in blood is a bad predictor
for cholinergic clinical signs due to acute OP poisoning
(Bueters et al. 2003). Logistic regression analysis of the
present results, using lower doses of OP compared to that
study, revealed the inhibition of AChE in blood to be a
good predictor for the probability of chewing, shivering,
seizures, convulsions and tremor, but not for respiratory
distress and death (Fig. 7a). This shows that seizures are
accompanied and not necessarily preceded by mild clinical
signs. It also shows that poisoning with lower doses does
not ameliorate the chance of development of severe clinical
signs. The most severe sign well predicted by blood AChE
activity was seizure development, mostly held responsible
for adverse effects at the long term. The toxicokinetics of
soman are not linear, higher doses lead to relatively much
higher AUC and less rapid clearance than following lower
doses (Van der Schans et al. 2008). This implicates that at
higher doses, binding sites will more rapidly be saturated,
leading to a more rapid development of clinical signs. In
contrast, at lower doses, as used in the present study,
clearance is higher, leading to a more gradual and slower
pattern of poisoning, and AChE activity in blood might
more accurately reﬂect the levels of neuronal AChE
activity, resulting in a better prediction of development of
clinical signs.
These ﬁndings underscore that protection of AChE
activity is a primary target for treatment in case of OP
exposure. Only at the lowest dose of 3.1 mg/kg and not at
both higher doses of 9 and 18 mg/kg, obidoxime showed
signiﬁcant reactivation in the medulla oblongata, but not in
blood or other brain parts. The efﬁcacy of the lowest dose
of obidoxime on the development of convulsions, seizures
and respiratory deterioration might be explained by the
higher level of AChE activity found in the medulla
oblongata. It might be speculated that some reactivation of
soman-inhibited AChE occurs in the ﬁrst minutes after the
administration of obidoxime, before our ﬁrst measuring
point and ageing of soman-inhibited AChE. The higher
number of binding sites for soman in blood probably
reduced the soman load that entered the brain, causing less
inhibition in the medulla oblongata. The decline of thera-
peutic efﬁcacy at higher doses of obidoxime might be
ascribed to the inhibitory actions that phosphonylated
obidoxime exerts on AChE (Harvey et al. 1986; van Helden
et al. 1994). The slight delay of complete inhibition of
AChE in the blood and probably also in the brain by obi-
doxime might explain its therapeutic efﬁcacy, as only little
amounts of active AChE in the brain are sufﬁcient to
improve the aforementioned parameters (Bueters et al.
2003). In addition, suspected direct pharmacological
actions of obidoxime might facilitate adaptive processes
(van Helden et al. 1994, 1996). Obidoxime is capable of
increasing ACh release two- to threefold in the absence of
AChE inhibitors, which can contribute to accelerated
adaptation of cholinergic synapses to increased ACh levels
and thereby to protection against the toxic load of soman
(Oydvin et al. 2005). Second, obidoxime is known to
allosterically modulate the mAChR2 receptor (Gnagey and
Ellis 1996; Grossmuller et al. 2006; Kloog et al. 1985),
which is involved in cholinergic feedback mechanisms
(Segal 1989).
Additionofatropinesulphatetoobidoximeinexactlyone
autoinjector equivalent (0.03 mg/kg) had no added value at
all.Ahigherdoseofatropine,3 mg/kg,adosesimilartothat
often used in OP-research, revealed some protection, in
Fig. 7 Continuous relationships of the occurrence of soman-induced
signs obtained with logistic regression analysis. a The relationship
between AChE activity in blood and clinical signs of animals
poisoned with three doses of soman but no treatment (n = 18). b The
relationship between the probability of seizures and the residual
AChE of animals poisoned with 30 lg/kg soman treated at 1 min
post-poisoning with single drugs or their combinations (n = 6–18 per
treatment)
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123particular against extensive salivation and convulsions, and
to a lesser extent to seizure development and respiration. In
contrast to low autoinjector-equivalent doses, only such
higher doses showed to be an effective support for anti-
convulsant treatments (Shih et al. 2007). In addition, we
show that the combined treatment with atropine and
obidoxime enhances survival in case of poisoning with
44 lg/kg of soman. Other researchers have showed higher
efﬁcacy using relatively high doses of the much more potent
mAChR antagonist scopolamine. It might therefore be
advisable to replace atropine by scopolamine, although
extrapolation of the dose from animal research to the human
situation remains difﬁcult (Wetherell et al. 2007).
Physostigmine was previously proposed as alternative
immediate treatment against 5 LD50 of soman (Wetherell
et al. 2006, 2007). In case of poisoning with soman,
physostigmine, at a similar dose as used in our study, was
rather effective, and its efﬁcacy increased when high
doses of HI-6 were used, which was ascribed to the
competition with incoming soman for binding sites
(Wetherell et al. 2007). In the present study, the thera-
peutic window of physostigmine appeared to be very
small. We showed that 0.1 mg/kg physostigmine provided
some protection when administered at 1 min after poi-
soning and that 0.3 mg/kg showed to be most effective,
but 0.8 mg/kg appeared to aggravate clinical signs and to
diminish survival. Residual AChE activity was measured
using a modiﬁed Ellman reaction, revealing the AChE
fraction that was inhibited by physostigmine in vivo.
During sample preparation, physostigmine-inhibited
AChE was likely to fully decarbamylate because of its
short half-life of approximately 32 min in vitro (Wetherell
and French 1991). Therefore, the inhibited fraction most
likely reﬂects the portion of AChE inhibited by soman,
because without treatment, the dose of soman used was
sufﬁcient to fully inhibit AChE activity in blood. Mea-
surements of residual AChE activity showed that the
lowest dose (0.1 mg/kg) provided the lowest protection of
AChE by physostigmine, whereas the higher doses 0.3
and 0.8 mg/kg inhibited a similar fraction of AChE
(*50% of activity). These ﬁndings indicate that the small
therapeutic window is probably due to the carbamylation
rate of physostigmine, being too low at a dose of 0.1 mg/kg,
whereas the carbamylation rate of physostigmine excee-
ded decarbamylation at a dose of 0.8 mg/kg. Only at the
middle dose tested, 0.3 mg/kg, carbamylation and
decarbamylation were balanced leading to protection of
sufﬁcient amounts of AChE to exert protection. Although
the measurements of residual AChE activity in animals
receiving postponed treatment with physostigmine did not
reveal a signiﬁcant decline or protection of AChE activity,
our results show that postponed treatment with a dose of
0.3 mg/kg physostigmine clearly led to a lower survival
rate and loss of therapeutic efﬁcacy in these animals.
These results indicate that postponed treatment with
physostigmine induces an additional increase in AChE
inhibition in blood and brain to that already brought about
by soman. This implies that administration of physostig-
mine can only be protective when a considerable fraction
of AChE is not yet occupied by soman, which was
accomplished by the 1-min treatment.
To compare all treatments for their mechanism of
action, logistic regression analysis was performed to
estimate the probability of seizure development at certain
levels of blood AChE activity in animals receiving dif-
ferent treatments after soman poisoning (30 lg/kg)
(Fig. 7b). This analysis showed that when atropine or
obidoxime or their combination was used as a treatment,
the seizure probability dramatically decreased at similar
AChE activity, conﬁrming the mechanism of atropine and
obidoxime in this study to be largely independent from
AChE reactivation. However, when physostigmine treat-
ment without atropine was employed, seizure probability
at similar AChE activity remained comparable to that in
untreated animals. This indicates that the efﬁcacy of
physostigmine is probably only due to its ability to pre-
vent soman from binding to AChE, thereby reserving a
decarbamylating pool of AChE while the OP is degraded,
and is not due to suspected effects on nicotinic receptors
(Harris et al. 1990).
In conclusion, the present results show that the combi-
nation atropine and obidoxime is hardly effective against
soman poisoning, even at a fairly low toxic load as used in
the present study. However, for nerve agents that are more
prone to reactivation than soman, this regimen is expected
to show higher efﬁcacy. Although physostigmine signiﬁ-
cantly improved therapeutic outcomes, there might be
some drawbacks to adding physostigmine to the current
autoinjector components. In practice, treatment will only
be administered at appearance of toxic signs, indicating
inhibition of the major fraction AChE by nerve agent. In
particular, at high levels of nerve agent poisoning, carba-
mates will fully inhibit the small remaining pool of AChE,
thereby further pushing cholinergic overstimulation and
worsen the clinical condition. Treatment of OP poisoning
with a carbamate, such as physostigmine, should therefore
carefully be re-evaluated.
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